Kevin Pan – CEO, Asieris, China
Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary…
Asieris Pharmaceuticals, founded in March 2010 in China Medical City in Jiangsu Taizhou, is the only China-based, globally-oriented company specializing in the R&D of new drugs for the treatment of genitourinary tumours and related diseases.
Our professional teams are located in Shanghai, Beijing, and Taizhou (Jiangsu), as well as in the United States. With our focus on genitourinary tumours and related diseases, our goal is to establish a leading position in this field with our own unique strategies. Through the “twin engines” of proprietary R&D and in-licensing, we explore the global values of proprietary first-in-class new drugs of breakthrough potential. Meanwhile, we in-license late-stage or marketed new drugs from overseas for the Chinese market to enhance our product pipeline and allow us to quickly establish our leadership position in the domestic market.
Contact
12F, Building 56，No.1000 Jinhai Road, City of Elite, Pudong, Shanghai, China
Tel: +(86) 21 68585280
Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary…
VMS Group was founded in 2006 and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong. Apart…
In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due…
Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma…
Han Yahui from Chinese folic acid specialist Scrianen outlines her company’s role in keeping mothers and newborns healthy in China, Scrianen’s approach to international partnerships, and the next horizons in…
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
Prof. Song Ruilin outlines the Chinese (bio)pharmaceutical industry’s progress across the three key pillars of innovation, industrialization, and internationalization in recent years. While a downturn in the global economy and…
Haematological oncologist Dr Raymond Liang, gives his take on the adoption and challenges of CAR-T therapy in Hong Kong, the necessity of collaboration with mainland China for patient referrals and…
Chinese biotech Jacobio has made remarkable strides in pioneering first-in-class drug research, with their SHP2 inhibitor project only the second globally to initiate a clinical trial for a novel target…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
The latest news from Chinese pharma, including progress on the US Senate bill targeting BGI and WuXi AppTec, a report on why drug research is slowing in the country, and…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
US Congress has highlighted Chinese biotechnology firms, including giants WuXi and BGI, as posing a risk to the country’s national security. PharmaBoardroom takes a look at why the US is…
See our Cookie Privacy Policy Here
